Skip to search formSkip to main contentSkip to account menu

CALGB 9251 Regimen

A regimen comprised of a prephase (or cytoreductive phase), followed by two different chemotherapy regimens, given on an alternating schedule and… 
National Institutes of Health

Related topics

Related topics

12 relations
CyclophosphamideCytarabineDexamethasoneDoxorubicin

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Effect of Pretreatment Renal Function on Treatment and Clinical Outcomes in the Adjuvant Treatment of Older Women With Breast Cancer: Alliance A171201, an Ancillary Study of CALGB/CTSU 49907.
PURPOSE CALGB 49907 showed the superiority of standard therapy, which included either cyclophosphamide/doxorubicin (AC) or… 
Highly Cited
2015
Highly Cited
2015
Randomized Phase III Trial of Paclitaxel Once Per Week Compared With Nanoparticle Albumin-Bound Nab-Paclitaxel Once Per Week or Ixabepilone With Bevacizumab As First-Line Chemotherapy for Locally…
PURPOSE We compared nab-paclitaxel or ixabepilone once per week to paclitaxel with bevacizumab as first-line therapy for patients… 
2015
2015
Breast cancer: Weekly paclitaxel—still preferred first-line taxane for mBC
Taxane-based regimens are among the preferred first-line chemotherapy options for metastatic breast cancer, with weekly… 
2009
2009
Breast cancer molecular profiles and tumor response of neoadjuvant doxorubicin and paclitaxel: The I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657).
LBA515 Background: I-SPY is a multi-center trial designed to identify predictive markers of pathological complete response (pCR… 
2009
2009
Discovery of a new phospho-HER2+/FISH- molecular subtype of human breast cancer by functional pathway mapping.
11009 Background: Effective treatment of breast cancer through the targeting of the HER2 protein in human breast cancer… 
Review
2008
Review
2008
Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235.
Review
2006
Review
2006
Cancer and Leukemia Group B Clinical Research Associates Committee
The Cancer and Leukemia Group B is dedicated to developing and implementing training programs that will enhance the skills and… 
Highly Cited
2004
Highly Cited
2004
Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803)
3500 Background: Irinotecan prolongs survival in second line 5FU-refractory metastatic colorectal cancer (MCRC). First line… 
Highly Cited
2004
Highly Cited
2004
Irinotecan plus fluorouracil/leucovorin (IFL) versus fluorouracil/leucovorin alone (FL) in stage III colon cancer (intergroup trial CALGB C89803).
3500 Background: Irinotecan prolongs survival in second line 5FU-refractory metastatic colorectal cancer (MCRC). First line… 
2004
2004
A reduction in the rate of PSA rise following chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) predicts survival: Results of a pooled analysis of CALGB HRPC trials.
4506 Background: A prostate-specific antigen (PSA) decline of > 50% is associated with a prolongation in survival for patients… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)